MORF News and Press, Morphic Holding Inc. From 07/11/21

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

Morphic Therapeutic (MORF) said that MORF-057, an oral small-molecule inhibitor of the α4β7 showed dose-dependent receptor occupancy in a Phase 1 trial for inflammatory bowel disease ((IBD)).The results were shared in a presentation at the Congress ((CACOX)) of the Eur...

MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset migration and CCR9 transcript levels provide early proof of biology...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead U.S. markets are only open for four trading days after taking a breather for the Independence Day holiday. It is a quiet...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

WALTHAM, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss resul...

Insider buying increased last week. Notable Insider Buys: PennyMac Financial Services, Inc., Morphic Holding, Inc., Bumble Inc., Clene Inc., Forum Energy Technologies, Inc. Notable Insider Sells: Walmart Inc., Facebook, Inc., Squarespace, Inc., Sun Communities, Inc., XPEL, Inc. ...

Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study ...

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are schedule...

Morphic (MORF): Q1 GAAP EPS of -$0.63 misses by $0.09.Revenue of $3.26M (-41.8% Y/Y) misses by $5.07M.Press Release For further details see: Morphic EPS misses by $0.09, misses on revenue